INTRODUCTION AND OBJECTIVES:
There is a dearth of evidence showing a long-term benefit of performing debulking procedure in small volume prostates (<40grams), with no evidence in using 180-W XPS-greenlight system in this population. Our objective was to characterize the long term clinical and symptomatic benefit of the 180-W XPS-Greenlight laser in patients with small volume prostates.
METHODS: A retrospective analysis of 58 patients who underwent 180-W XPS-laser PVP vaporization of the prostate between 2012 and 2016 at three tertiary medical centers. We included all comers with prostates less than 40 grams with clinical evidence of bladder outlet obstruction.
RESULTS: The average age of men who underwent PVP of the prostate was 67.8AE10.9 years old, with an average BMI of 29.7AE3.9. The average prostate volume was 29AE6.7mL, five patients were found to have a significant intravesicular median lobe. Three patients had pre-operative retention requiring catheterization, 45 patients were using an alpha blocker and 41 were using a 5-alpha reductase inhibitor. The average operative time was 45.1AE22.1 minutes, laser time of 20.9AE 13 minutes, and energy of 146AE96.8 kilojoules. All patients were discharged from the hospital within 48 hours of the procedure, five patients were discharged with a catheter. The median follow up time was 6 months (IQR 3-22.5), there were 12 complications within 30 days, including 2 patients with persistent retention, 4 patients had urinary tract infections, 4 patients had severe urgency requiring medications, one patient had intermittent hematuria and 1 patient had a paraphimosis. There was no incidence of stricture or bladder neck up to four years of follow up. The IPSS score improved from was 22.8AE7 at baseline 0.7AE7 (p<0.01) and 6.31AE4.4 (p<0.01) at 30 and 180 days, respectively. The maximal flow rate improved from 7.7AE4.6 ml/sec at baseline to 17.25AE9. INTRODUCTION AND OBJECTIVES: According to AUA guidelines Greenlight PVP 532-nm laser vaporization of the prostate should be considered in patients receiving anticoagulant medication or with a high cardiovascular risk. We sought to examine the functional and complications outcomes of high risk patients with cardiovascular disease necessitating maintenance of anticoagulation therapy (ACO).
METHODS: Retrospective analysis of prospectively maintained institutional database was performed. Men were stratified according to ACO treatment status defined as the usage of anti-vitamin K, Heparin, direct thrombin inhibitor or and anti-Xa. Complications at 30 and 90 days according to Clavien classification and functional outcomes (IPSS, Qmax and PVR) were analyzed up to 5-years follow-up.
RESULTS: A total of 39 (10%) patients were on ACO including 8 patients with prosthetic cardiac valve, 26 patients with malignant arrhythmias and 27 with coronary cardiac disease. ACO patients were older (75 vs 67 years, p<0.01) and with more systemic disease defined by ASA score. Men with ACO were more likely to fail first trial of void, had significant longer catheterization time 1.7 vs 1 days and longer hospitalization 2.5 vs 0.5 days respectively (p<0.01 for all). ACO men had also higher 30 days readmission rate of 16% and higher rate of hematuria observed in almost 1/3 of the cases. Functional outcomes were significantly improved and equivalent to non ACO patients at all endpoints including at 5-year.
CONCLUSIONS: This is the first study to look at safety and functional outcomes of patients with cardiovascular disease requiring ACO with 5 years follow-up. PVP provide significant and durable treatment for symptomatic BPH in these high-risk ACO patient. However treatment comes with an increased risk of bleeding e332 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 related complication implying longer catheterization and hospitalization that should be discussed during pre-operative patient counseling. 
INTRODUCTION AND OBJECTIVES: As per Goliath trial, Greenlight laser (XPS) Photoselective Vaporization of the prostate (GL.PVP) is non-inferior to TURP in reduction of LUTs secondary to
BPH with all advantages of laser. Plasma Kinetic vaporization of the prostate (PKVP) is a potential contender to the evolving Greenlight PVP. In this study, non-inferiority of PKVP compared to GL.PVP, in reduction of LUTS secondary to BPH, was tested in a randomized trial.
METHODS: Between November 2014 and October 2015, 120 patients with complicated BPH (size 30-80 cc) were randomized to GL.PVP and PKVP.Patients were assessed postoperatively using I-PSS, QOL, Qmax and PVR (at 1, 4, and 12 months), IIEF-15 and PSA (at 4 and 12 months). Non-inferiority of I-PSS at 1 year was evaluated using a 1-sided test at 5% level of significance. The statistical significance of other comparators was assessed at the (2-sided) 5% level.
RESULTS: At time of analysis 58 GL.PVP and 61 PKVP procedures were included. Patients' demographics, prostate size, indications of intervention and perioperative parameters were comparable between both groups apart from more perioperative irrigant fluid use in GL.PVP (P ¼0.014). More postoperative dysuria was reported after PKVP, dysuria visual analogue scale 4(0-10) vs. 6(0-10), P¼0.005 in GL.PVP and PKVP respectively. Urinary outcome measures revealed significant comparable improvement in both groups at different follow up points either in the net value or in the percentage improvement from baseline measure. At 1 year, median IPSS was 6 (1:25) vs 5 (1:18) P¼0.7, median QoL was 1 (0:5) vs 1 (1:5) P¼0.84, mean Q max was 22AE9.4 vs 20AE8.5 ml/sec P¼0.42, median PVR was 20 (0:97) vs 25 (0:109) ml P¼0.14, in GL.PVP and PKVP respectively. Median postoperative change in PSA was 63.5% (-54:95) following GL.PVP vs 31.6% (-66:30) after PKVP, P¼0.027. Both groups showed comparable perioperative and late postoperative complication and re-intervention rate during the first year. Among sexually active men (25%), there was significant reduction of IIEF-15 score following PKVP in comparison to GL.PVP CONCLUSIONS: PKVP is a safe and effective modality in treating patients with LUTS secondary to small to moderate sized BPH. In terms of symptoms control, it was not inferior to GL.PVP at 1 year. Long-term durability of the outcome is critical considering the difference in postoperative PSA reduction. Impact on the sexual function should be considered for further evaluation in a larger cohort of sexually active men. METHODS: We conducted a single-site prospective, randomized study of Greenlight XPS PVP vs BiVAP in men age ! 18 years with symptomatic BPH defined by American Urological Association (AUA) symptom score ! 15, maximum urinary flow rate (QMax) < 15mL/sec, and prostate volume ! 30g. Exclusion criteria included prior surgical treatment for BPH, post-void residual (PVR) > 300mL, and prostate-specific antigen (PSA) ! 4 ng/mL. Eligible men were randomized in a 1:1 ratio. Men were followed at 1, 3, 6, and 12 months post-operatively for assessment of the primary outcomes, AUA symptom score and QMax. Chi-square and t-tests were utilized where applicable.
RESULTS: Baseline characteristics for PVP vs BiVAP were similar with regard to age, race, Qmax, PVR, AUA Symptom score, and prostate volume (59.2 AE 28.8 vs 56.1 AE 22.8 g, p¼0.62). There was no difference in peri-operative outcomes including mean length of procedure (48.4 AE 30.6 vs 49.8 AE 23.7 mins, p¼0.83), length of stay (100% vs 100% discharged within 24 hrs, p¼1.00), and length of catheterization (76.7% vs 71.4% catheter removal within 24 hrs, p¼0.78). At 12 months, mean improvement in AUA symptom score was slightly greater for PVP vs BiVAP, approaching but not reaching statistical significance (-14.7 AE 9.0 vs -10.5 AE 8.6, p¼0.10). At 12 months, there were no differences in mean Qmax, PVR, or prostate volume between the groups (all p > 0.05).
CONCLUSIONS: Both Greenlight PVP and BiVAP TURP are safe and effective treatments for men with symptomatic BPH desiring surgery. Selection of operative approach should be driven by unique patient characteristics and surgeon experience.
